OF THE
TIMES
"[T]he Court finds that fluoridation of water at 0.7 milligrams per liter ("mg/L") - the level presently considered "optimal" in the United States - poses an unreasonable risk of reduced IQ in children.... [A] risk sufficient to require the EPA to engage with a regulatory response...."The NTP report referred to above can be found here. While we wait for the EPA to take the next step, many municipalities have already acted to remove fluoride from their water systems.
"There is little dispute in this suit as to whether fluoride poses a hazard to human health. Indeed, EPA's own expert agrees that fluoride is hazardous at some level of exposure. And ample evidence establishes that a mother's exposure to fluoride during pregnancy is associated with IQ decrements in her offspring. The United States National Toxicology Program ("NTP") - the federal agency regarded as experts in toxicity.... concluded that fluoride is indeed associated with reduced IQ in children, at least at exposure levels at or above 1.5 mg/L (i.e., "higher" exposure levels)...."
"In all, there is substantial and scientifically credible evidence establishing that fluoride poses a risk to human health; it is associated with a reduction in the IQ of children and is hazardous at dosages that are far too close to fluoride levels in the drinking water of the United States. And this risk is unreasonable under Amended TSCA. Reduced IQ poses serious harm. Studies have linked IQ decrements of even one or two points to e.g., reduced educational attainment, employment status, productivity, and earned wages."
The long-term benefits of these drugs could be monumental in our approach to tackling obesity. For many people, these weight-loss jabs will be life-changing, help them get back to work, and ease the demands on our NHS.The specific drug in question is "Mounjaro", produced by pharma giant Lilly to compete with the Novo Nordisk's Ozempic/ Wegovy. And the first phase of the scheme is a five-year trial on 3000 obese people in the Manchester area, described in another Telegraph article:
Up to 3,000 obese patients - a mixture of those in and out of work, and on sickness leave - will be recruited for a five-year study that will explore whether the medication boosts productivity and could bring more people back to the workplace.It was also announced that Lilly - the biggest of Big Pharma vultures - will be "investing" £280 million in the scheme.
a collaboration that includes exploring new ways of delivering health and care services to people living with obesity, and a five-year real-world study of a cutting-edge obesity treatment.""Collaboration" is doing some work in that sentence.
Comment: See also: